All In Biotech

Drug Trial Radar · NCT00061633

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

Last checked: Nov 19, 2026Latest source record: Jan 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 169 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

169

Actual

Start

Jun 2003

Primary completion

Jan 2004

Study completion Jan 2004

Sponsor

Lead sponsor
Cumberland PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 2, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria. This study will measure how well TD-6424 (Telavancin) can control infections and whether this drug can be safely given to patients.

Conditions

  • Infections, Gram-Positive Bacterial
  • Abscess
  • Burns
  • Cellulitis
  • Ulcer
  • Wound Infections

Interventions

  • TelavancinDrug

    Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days

  • Vancomycin or antistaphylococcal penicillinDrug

    Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) PopulationTime frame: 7-14 days following end of antibiotic treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • eStudy Site, 3450 Bonita Road, Ste 201

    Chula Vista, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.